M David Percival

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Continuous spectrophotometric assay amenable to 96-well plate format for prostaglandin E synthase activity
    M David Percival
    Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, P O Box 1005, Pointe Claire Dorval, Kirkland, Que, Canada H9R 4P8
    Anal Biochem 313:307-10. 2003
  2. doi Pharmacological and genetic evidence that cathepsin B is not the physiological activator of rodent prorenin
    M David Percival
    Department of In Vitro Sciences, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    Biol Chem 391:1469-73. 2010
  3. ncbi Inhibition of cathepsin K by nitric oxide donors: evidence for the formation of mixed disulfides and a sulfenic acid
    M D Percival
    Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    Biochemistry 38:13574-83. 1999
  4. pmc Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor
    D Riendeau
    Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    Br J Pharmacol 121:105-17. 1997
  5. pmc A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin
    M Ouellet
    Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Kirkland, QC, Canada
    Proc Natl Acad Sci U S A 98:14583-8. 2001
  6. ncbi Mechanism of acetaminophen inhibition of cyclooxygenase isoforms
    M Ouellet
    Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    Arch Biochem Biophys 387:273-80. 2001
  7. ncbi Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2
    D Riendeau
    Department of Pharmacology, Biochemistry, and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    J Pharmacol Exp Ther 296:558-66. 2001
  8. ncbi Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
    C C Chan
    Departments of Pharmacology, Biochemistry and Molecular Biology, and Medicinal Chemistry, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    J Pharmacol Exp Ther 290:551-60. 1999
  9. ncbi Investigation of human cyclooxygenase-2 glycosylation heterogeneity and protein expression in insect and mammalian cell expression systems
    M D Percival
    Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Quebec, Canada
    Protein Expr Purif 9:388-98. 1997
  10. ncbi Thermodynamic analysis of the binding of aromatic hydroxamic acid analogues to ferric horseradish peroxidase
    S M Aitken
    Department of Chemistry and Biochemistry, Concordia University, 1455 de Maisonneuve Boulevard West, Montreal, Quebec, Canada
    Biochemistry 40:13980-9. 2001

Collaborators

Detail Information

Publications12

  1. ncbi Continuous spectrophotometric assay amenable to 96-well plate format for prostaglandin E synthase activity
    M David Percival
    Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, P O Box 1005, Pointe Claire Dorval, Kirkland, Que, Canada H9R 4P8
    Anal Biochem 313:307-10. 2003
    ..PGDH is relatively specific for PGE(2) over the substrate for the PGES reaction, PGH(2), allowing a highly reproducible assay of PGES activity to be obtained...
  2. doi Pharmacological and genetic evidence that cathepsin B is not the physiological activator of rodent prorenin
    M David Percival
    Department of In Vitro Sciences, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    Biol Chem 391:1469-73. 2010
    ..We conclude that cathepsin B does not play a significant role in this process in rodents...
  3. ncbi Inhibition of cathepsin K by nitric oxide donors: evidence for the formation of mixed disulfides and a sulfenic acid
    M D Percival
    Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    Biochemistry 38:13574-83. 1999
    ..This work also shows that oxidative thiol modifications besides S-nitrosylation should be considered when the effects of NO and NO donors on critical thiol-containing proteins are investigated...
  4. pmc Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor
    D Riendeau
    Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    Br J Pharmacol 121:105-17. 1997
    ....
  5. pmc A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin
    M Ouellet
    Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Kirkland, QC, Canada
    Proc Natl Acad Sci U S A 98:14583-8. 2001
    ..These results show that a low affinity for Cox-1 and a high degree of Cox-2 selectivity confers a low potential to block aspirin inhibition of platelet Cox-1, consistent with the results of clinical studies...
  6. ncbi Mechanism of acetaminophen inhibition of cyclooxygenase isoforms
    M Ouellet
    Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    Arch Biochem Biophys 387:273-80. 2001
    ..Inhibition would therefore be more effective under conditions of low peroxide concentration, consistent with the known tissue selectivity of acetaminophen...
  7. ncbi Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2
    D Riendeau
    Department of Pharmacology, Biochemistry, and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    J Pharmacol Exp Ther 296:558-66. 2001
    ....
  8. ncbi Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
    C C Chan
    Departments of Pharmacology, Biochemistry and Molecular Biology, and Medicinal Chemistry, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    J Pharmacol Exp Ther 290:551-60. 1999
    ....
  9. ncbi Investigation of human cyclooxygenase-2 glycosylation heterogeneity and protein expression in insect and mammalian cell expression systems
    M D Percival
    Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Quebec, Canada
    Protein Expr Purif 9:388-98. 1997
    ..The difference between the highest mass peaks of the two envelopes, of approximately 1500 Da, is consistent with the wild-type enzyme containing an additional high mannose oligosaccharide...
  10. ncbi Thermodynamic analysis of the binding of aromatic hydroxamic acid analogues to ferric horseradish peroxidase
    S M Aitken
    Department of Chemistry and Biochemistry, Concordia University, 1455 de Maisonneuve Boulevard West, Montreal, Quebec, Canada
    Biochemistry 40:13980-9. 2001
    ..Examination of the thermodynamics of binding of ring-substituted hyrazides to HRPC reveals that the binding affinities of aromatic donors are highly sensitive to the position and nature of the ring substituent...
  11. ncbi Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L
    J P Falgueyret
    Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, 16711 TransCanada Highway, Kirkland, Quebec H9H 3L1, Canada
    J Med Chem 44:94-104. 2001
    ..7 M. 1-Cyanopyrrolidine represents a new class of nonpeptidic compounds that inhibit cathepsin K and L activity and proteolysis of bone collagen...
  12. ncbi Therapeutic utility and medicinal chemistry of cathepsin C inhibitors
    Daniel Guay
    Department of Medicinal Chemistry, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    Curr Top Med Chem 10:708-16. 2010
    ....